Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Abstract Germline mutations in BRCA1 or BRCA2 exist in ~2–7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting. We have previously reported a phase II neoadjuvant trial of single agent talazoparib for patients with germline BRCA pathogenic variants w...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Xuan Liu, Zhongqi Ge, Fei Yang, Alejandro Contreras, Sanghoon Lee, Jason B. White, Yiling Lu, Marilyne Labrie, Banu K. Arun, Stacy L. Moulder, Gordon B. Mills, Helen Piwnica-Worms, Jennifer K. Litton, Jeffrey T. Chang
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2022-05-01
Serija:	npj Breast Cancer
Online dostop:	https://doi.org/10.1038/s41523-022-00427-9
Oznake:	Označite Brez oznak, prvi označite!